Table 1.
Characteristics of the 2153 patients at the initiation of the biologic
| Patients' characteristics | ||
| Median age, years (n = 2153) | 46.0 (35.0–57.0) | |
| Female sex (n = 2153) | 850 (39.5) | |
| Obesity (BMI ≥ 30 kg/m2) (n = 1914) | 554 (28.9) | |
| Alcohol consumption (n = 1476) | 1004 (68.0) | |
| Liver disease (n = 2120) | 43 (2.0) | |
| Psoriasis | ||
| Median disease duration, years (n = 1960) | 15.0 (7.0–25.0) | |
| Median PASI score (n = 1622) | 11.4 (7.1–13.3) | |
| Median DLQI score (n = 1273) | 10.0 (5.0–16.0) | |
| Psoriasis clinical form (n = 2113) | ||
| Plaque psoriasis | 1905 (90.2) | |
| Guttate | 435 (20.6) | |
| Erythrodermic | 45 (2.1) | |
| Onychopathy | 168 (8.0) | |
| Localized pustular | 83 (3.9) | |
| Generalized pustular | 9 (0.4) | |
| Treatments | ||
| Concomitant treatment with methotrexate (n = 2153) | 72 (3.3) | |
| First biologic (n = 2153) | ||
| TNF‐alpha inhibitors | Adalimumab | 832 (38.6) |
| Etanercept | 340 (15.8) | |
| Infliximab | 44 (2.0) | |
| Certolizumab | 6 (0.3) | |
| IL‐12 23 inhibitor | Ustekinumab | 732 (34.0) |
| IL‐17 inhibitors | Secukinumab | 78 (3.6) |
| Ixekizumab | 63 (2.9) | |
| Brodalumab | 13 (0.6) | |
| IL‐23 inhibitor | Guselkumab | 45 (2.1) |
Median and interquartile range for continuous variables, n (%) for categorical variables
DLQI, Disease Quality of Life Index; PASI, Psoriasis Activity Skin Index.